Trial · NCT03691649
Adverse events129
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 129
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctival hyperaemia | Eye disorders | DE-117 Ophthalmic Solution (Double Masked Treatment Period) | 13 | 211 | |
| other | Conjunctival hyperaemia | Eye disorders | Timolol Maleate Ophthalmic Solution 0.5% (Double Masked Treatment Period) | 10 | 215 | |
| other | Conjunctival hyperaemia | Eye disorders | DE-117 Ophthalmic Solution (Open Label Treatment Period) | 12 | 377 | |
| other | Vision blurred | Eye disorders | DE-117 Ophthalmic Solution (Double Masked Treatment Period) | 11 | 211 | |
| other | Vision blurred | Eye disorders | Timolol Maleate Ophthalmic Solution 0.5% (Double Masked Treatment Period) | 3 | 215 | |
| other | Vision blurred | Eye disorders | DE-117 Ophthalmic Solution (Open Label Treatment Period) | 14 | 377 | |
| other | Photophobia | Eye disorders | DE-117 Ophthalmic Solution (Double Masked Treatment Period) | 10 | 211 | |
| other | Photophobia | Eye disorders | Timolol Maleate Ophthalmic Solution 0.5% (Double Masked Treatment Period) | 1 | 215 | |
| other | Photophobia | Eye disorders | DE-117 Ophthalmic Solution (Open Label Treatment Period) | 4 | 377 | |
| other | Ocular hyperaemia | Eye disorders | DE-117 Ophthalmic Solution (Double Masked Treatment Period) | 6 | 211 | |
| other | Ocular hyperaemia | Eye disorders | Timolol Maleate Ophthalmic Solution 0.5% (Double Masked Treatment Period) | 4 | 215 | |
| other | Ocular hyperaemia | Eye disorders | DE-117 Ophthalmic Solution (Open Label Treatment Period) | 0 | 377 | |
| other | Dry eye | Eye disorders | DE-117 Ophthalmic Solution (Double Masked Treatment Period) | 4 | 211 | |
| other | Dry eye | Eye disorders | Timolol Maleate Ophthalmic Solution 0.5% (Double Masked Treatment Period) | 2 | 215 | |
| other | Dry eye | Eye disorders | DE-117 Ophthalmic Solution (Open Label Treatment Period) | 0 | 377 | |
| other | Eye pain | Eye disorders | DE-117 Ophthalmic Solution (Double Masked Treatment Period) | 4 | 211 | |
| other | Eye pain | Eye disorders | Timolol Maleate Ophthalmic Solution 0.5% (Double Masked Treatment Period) | 5 | 215 | |
| other | Eye pain | Eye disorders | DE-117 Ophthalmic Solution (Open Label Treatment Period) | 6 | 377 | |
| other | Visual impairment | Eye disorders | DE-117 Ophthalmic Solution (Double Masked Treatment Period) | 4 | 211 | |
| other | Visual impairment | Eye disorders | Timolol Maleate Ophthalmic Solution 0.5% (Double Masked Treatment Period) | 0 | 215 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03691649/events